Verve Therapeutics
Subsidiary of Eli Lilly (LLY)
Assets
(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Financial reports
Quarterly & interim (11)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q1 | — | $54M | $101M+ $401M short-term inv. | $31M | report ↗ |
View 10 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-Q3 | — | $50M | $163M+ $381M short-term inv. | $50M | report ↗ |
| 2024-Q2 | — | $51M | $146M+ $434M short-term inv. | $50M | report ↗ |
| 2024-Q1 | — | $48M | $149M+ $462M short-term inv. | $49M | report ↗ |
| 2023-Q3 | — | $44M | $83M+ $407M short-term inv. | $46M | report ↗ |
| 2023-Q2 | — | $47M | $75M+ $392M short-term inv. | $54M | report ↗ |
| 2023-Q1 | — | $47M | $89M+ $425M short-term inv. | $52M | report ↗ |
| 2022-Q3 | — | $35M | $282M+ $274M short-term inv. | $45M | report ↗ |
| 2022-Q2 | — | $33M | $78M+ $221M short-term inv. | $41M | report ↗ |
| 2022-Q1 | — | $24M | $97M+ $232M short-term inv. | $30M | report ↗ |
| 2021-Q3 | — | $18M | $153M+ $241M short-term inv. | $23M | report ↗ |
Annual history (4 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $204M | $177M+ $352M short-term inv. | $50M | report ↗ |
Verve Therapeutics reported R&D spend of $204.35M, up 10.5% YoY, cash and equivalents of $177.33M, and a net loss of $198.71M for fiscal year 2024.
Figures only: this period's report disclosed no narrative text